Article Information
PubMed
Published By
Print ISSN
Online ISSN
History
- Received for publication September 16, 2012
- Accepted for publication November 29, 2012
- Published online June 3, 2013.
Article Versions
- previous version (March 20, 2013 - 05:14).
- You are viewing the most recent version of this article.
Copyright & Usage
© 2013 by the Society of Nuclear Medicine and Molecular Imaging, Inc.
Author Information
- Ronald C. Walker1–3,
- Gary T. Smith1,2,
- Eric Liu3,4,
- Brandon Moore1,
- Jeff Clanton2 and
- Michael Stabin2
- 1Medical Imaging Service, Veterans Affairs Tennessee Valley Healthcare System, Nashville, Tennessee
- 2Department of Radiology and Radiological Sciences, Vanderbilt University Medical Center, Nashville, Tennessee
- 3Vanderbilt-Ingram Cancer Center, Nashville, Tennessee; and
- 4Department of Surgery, Vanderbilt University Medical Center, Nashville, Tennessee
- For correspondence or reprints contact: Ronald C. Walker, Veterans Affairs Tennessee Valley Healthcare System and Vanderbilt University Medical Center, CCC-1121 MCN, 1161 21st Ave. S., Nashville, TN 37232-2675. E-mail: ronald.walker{at}vanderbilt.edu
Statistics from Altmetric.com
Cited By...
Article usage
Jump to section
Related Articles
Cited By...
- Safety, Biodistribution, and Radiation Dosimetry of the 68Ga-Labeled Minigastrin Analog DOTA-MGS5 in Patients with Advanced Medullary Thyroid Cancer and Other Neuroendocrine Tumors
- Preclinical Characterization of DPI-4452: A 68Ga/177Lu Theranostic Ligand for Carbonic Anhydrase IX
- Preclinical Comparison of the 64Cu- and 68Ga-Labeled GRPR-Targeted Compounds RM2 and AMTG, as Well as First-in-Humans [68Ga]Ga-AMTG PET/CT
- 64Cu Treatment Planning and 67Cu Therapy with Radiolabeled [64Cu/67Cu]MeCOSar-Octreotate in Subjects with Unresectable Multifocal Meningioma: Initial Results for Human Imaging, Safety, Biodistribution, and Radiation Dosimetry
- SNMMI Procedure Standard/EANM Practice Guideline for SSTR PET: Imaging Neuroendocrine Tumors
- 68Ga-DOTATATE PET/CT for Neuroblastoma Staging: Utility for Clinical Use
- Pulmonary carcinoid presenting in pregnancy with an unusual radiological feature
- MITIGATE-NeoBOMB1, a Phase I/IIa Study to Evaluate Safety, Pharmacokinetics, and Preliminary Imaging of 68Ga-NeoBOMB1, a Gastrin-Releasing Peptide Receptor Antagonist, in GIST Patients
- The GALANT trial: study protocol of a randomised placebo-controlled trial in patients with a 68Ga-DOTATATE PET-positive, clinically non-functioning pituitary macroadenoma on the effect of lanreotide on tumour size
- PET-Based Human Dosimetry of 68Ga-NODAGA-Exendin-4, a Tracer for {beta}-Cell Imaging
- Comparative Dosimetry for 68Ga-DOTATATE: Impact of Using Updated ICRP Phantoms, S Values, and Tissue-Weighting Factors
- Safety, Biodistribution, and Radiation Dosimetry of 68Ga-OPS202 in Patients with Gastroenteropancreatic Neuroendocrine Tumors: A Prospective Phase I Imaging Study
- Appropriate Use Criteria for Somatostatin Receptor PET Imaging in Neuroendocrine Tumors
- Current Concepts in 68Ga-DOTATATE Imaging of Neuroendocrine Neoplasms: Interpretation, Biodistribution, Dosimetry, and Molecular Strategies
- MANAGEMENT OF ENDOCRINE DISEASE: Flushing: current concepts
- Clinical Translation of a Click-Labeled 18F-Octreotate Radioligand for Imaging Neuroendocrine Tumors
- 68Ga-DOTATATE Compared with 111In-DTPA-Octreotide and Conventional Imaging for Pulmonary and Gastroenteropancreatic Neuroendocrine Tumors: A Systematic Review and Meta-Analysis
- Safety and Efficacy of 68Ga-DOTATATE PET/CT for Diagnosis, Staging, and Treatment Management of Neuroendocrine Tumors
- PET-Based Human Dosimetry of the Dimeric {alpha}v{beta}3 Integrin Ligand 68Ga-DOTA-E-[c(RGDfK)]2, a Potential Tracer for Imaging Tumor Angiogenesis
- Prospective Study of 68Ga-DOTATATE Positron Emission Tomography/Computed Tomography for Detecting Gastro-Entero-Pancreatic Neuroendocrine Tumors and Unknown Primary Sites
- 64Cu-DOTATATE PET for Neuroendocrine Tumors: A Prospective Head-to-Head Comparison with 111In-DTPA-Octreotide in 112 Patients
- Biodistribution and Radiation Dosimetry for the Chemokine Receptor CXCR4-Targeting Probe 68Ga-Pentixafor
- Peptide Receptor-Targeted Radionuclide Therapy Alters Inflammation in Atherosclerotic Plaques